Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
The journal of prevention of Alzheimer's disease
View this publicationSpeaker, Member, Steering-Committee Member
My group has focused on fluid biomarkers for the detection of different neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, especially in early, preclinical disease stages. In particular, we are interested in extracellular vesicles, not only as biomarkers but also as modulators of inflammation, their role in cell-cell communication and as potential carriers of disease pathology in neurodegeneration. We are employing data and biomaterial from patient cohorts as well as cell culture and murine models to elucidate the contribution of microglia to disease pathology in Alzheimer’s and Parkinson’s disease.
The journal of prevention of Alzheimer's disease
View this publicationNature aging
View this publicationFrontiers in aging neuroscience
View this publication